Literature DB >> 10348314

Bone marrow transplantation does not ameliorate the neurologic symptoms in mice deficient in hypoxanthine guanine phosphoribosyl transferase (HPRT).

B E Wojcik1, H A Jinnah, C E Muller-Sieburg, T Friedmann.   

Abstract

The use of bone marrow transplantation (BMT) for the treatment of genetic diseases with neurologic involvement has yielded mixed results. We have employed a mouse model of Lesch-Nyhan disease (LND) to assess the efficacy of BMT in ameliorating the neurologic manifestations of the disease. Adult HPRT-deficient mice exhibit a measurable decrease in striatal dopamine levels and a hypersensitivity to amphetamine. Marrow-ablated adult HPRT-deficient mice were transplanted with marrow from congenic HPRT-expressing mice. BMT altered neither the neurochemical nor the behavioral phenotypes in either HPRT-positive or HPRT-deficient mice. Barring any important species differences, these results suggest that BMT in its present form may not be an effective therapy for Lesch-Nyhan syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348314     DOI: 10.1023/a:1020661514514

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  46 in total

1.  Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation.

Authors:  P M Hoogerbrugge; K Suzuki; K Suzuki; B J Poorthuis; T Kobayashi; G Wagemaker; D W van Bekkum
Journal:  Science       Date:  1988-02-26       Impact factor: 47.728

Review 2.  The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome.

Authors:  W Krivit; L A Lockman; P A Watkins; J Hirsch; E G Shapiro
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells.

Authors:  V Maréchal; N Naffakh; O Danos; J M Heard
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

4.  CD4 is expressed on murine pluripotent hematopoietic stem cells.

Authors:  J P Wineman; G L Gilmore; C Gritzmacher; B E Torbett; C E Müller-Sieburg
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

5.  Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation.

Authors:  S Slavin; S Yatziv
Journal:  Science       Date:  1980-12-05       Impact factor: 47.728

6.  Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer.

Authors:  J H Wolfe; M S Sands; J E Barker; B Gwynn; L B Rowe; C A Vogler; E H Birkenmeier
Journal:  Nature       Date:  1992 Dec 24-31       Impact factor: 49.962

7.  Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII.

Authors:  M S Sands; L C Erway; C Vogler; W S Sly; E H Birkenmeier
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

8.  Glial cells metabolically cooperate: a potential requirement for gene replacement therapy.

Authors:  H E Gruber; R Koenker; L A Luchtman; R C Willis; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Localization of hypoxanthine-guanine phosphoribosyltransferase mRNA in the mouse brain by in situ hybridization.

Authors:  H A Jinnah; E J Hess; M C Wilson; F H Gage; T Friedmann
Journal:  Mol Cell Neurosci       Date:  1992-02       Impact factor: 4.314

10.  Separation of pluripotent stem cells and early B lymphocyte precursors with antibody Fall-3.

Authors:  C E Müller-Sieburg
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

View more
  1 in total

1.  Successful unrelated umbilical cord blood transplantation in Lesch-Nyhan syndrome.

Authors:  Krisztián Kállay; Zoltán Liptai; Gábor Benyó; Csaba Kassa; Veronika Goda; János Sinkó; Agnes Tóth; Gergely Kriván
Journal:  Metab Brain Dis       Date:  2012-02-17       Impact factor: 3.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.